MEETING BRIEF

ESMO 2023: eNSCLC

The latest news from ESMO 2023 on early non-small cell lung cancer (eNSCLC), including abstracts, featured articles, and information about the conference.

Curated ESMO 2023: eNSCLC eBook

A curated eBook featuring ESMO 2023: eNSCLC-focused studies, findings, and expert opinions.

READ THE STORY

Nov 30, 2023

The Importance of Detecting Early NSCLC

Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.

Nov 14, 2023

Medical Illustration showing lung cancer or bronchial carcinoma. 3d illustration

Can Radiotracers Predict Response to PD-L1 Inhibitors in Early NSCLC?

Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.

Nov 14, 2023

PW QUIZ

time watch pocketwatch early late timeframe

Q&A: Using Effective Treatments Earlier for NSCLC

“With lung cancer we’re treating more patients effectively today and even curing them because we're using our most effective therapies earlier.”

Nov 2, 2023

Higher res Kras driven lung cancer nsclc

Q&A: Availability of Multiple Options for NSCLC is “Very Exciting”

Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.

Oct 31, 2023

EXPLORE MORE

AI Demonstrates Ability to Predict Survival of Patients Receiving Immunotherapy

Oct 16, 2023

For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.

Nearly 40% With eNSCLC have EGFR Mutation